Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D06MLU
|
||||
| Former ID |
DNC009501
|
||||
| Drug Name |
(-)-dihydroclusin
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [527404] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C22H28O7
|
||||
| Canonical SMILES |
COC1=CC(=CC(=C1OC)OC)CC(CO)C(CC2=CC3=C(C=C2)OCO3)CO
|
||||
| InChI |
1S/C22H28O7/c1-25-20-9-15(10-21(26-2)22(20)27-3)7-17(12-24)16(11-23)6-14-4-5-18-19(8-14)29-13-28-18/h4-5,8-10,16-17,23-24H,6-7,11-13H2,1-3H3/t16-,17-/m0/s1
|
||||
| InChIKey |
FDHFWHRGVDRJIK-IRXDYDNUSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Cytochrome P450 3A4 | Target Info | Inhibitor | [527404] | |
| PathWhiz Pathway | Caffeine Metabolism | ||||
| Retinol Metabolism | |||||
| WikiPathways | Metapathway biotransformation | ||||
| Aflatoxin B1 metabolism | |||||
| Estrogen metabolism | |||||
| Benzo(a)pyrene metabolism | |||||
| Tamoxifen metabolism | |||||
| Tryptophan metabolism | |||||
| Oxidation by Cytochrome P450 | |||||
| Nuclear Receptors in Lipid Metabolism and Toxicity | |||||
| Nuclear Receptors Meta-Pathway | |||||
| Farnesoid X Receptor Pathway | |||||
| Vitamin D Receptor Pathway | |||||
| Felbamate Metabolism | |||||
| Lidocaine metabolism | |||||
| Nifedipine Activity | |||||
| Colchicine Metabolic Pathway | |||||
| Irinotecan Pathway | |||||
| Drug Induction of Bile Acid Pathway | |||||
| Fatty Acid Omega Oxidation | |||||
| Codeine and Morphine Metabolism | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.